Joel Greenblatt's PCRX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 44,939 shares of Pacira BioSciences, Inc. (PCRX) worth $1.02 M, representing 0.00% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in PCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 61,985 shares. Largest reduction occurred in Q2 2020, reducing 46,637 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Pacira BioSciences (PCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacira BioSciences (PCRX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +12,011 | Add 36.48% | 44,939 | $22.60 |
| Q4 2025 | -405 | Reduce 1.22% | 32,928 | $25.88 |
| Q3 2025 | -8,829 | Reduce 20.94% | 33,333 | $25.77 |
| Q2 2025 | -1,009 | Reduce 2.34% | 42,162 | $23.90 |
| Q1 2025 | -21,777 | Reduce 33.53% | 43,171 | $24.85 |
| Q4 2024 | -25,965 | Reduce 28.56% | 64,948 | $18.84 |
| Q3 2024 | +61,985 | Add 214.27% | 90,913 | $15.05 |
| Q2 2024 | +15,387 | Add 113.63% | 28,928 | $28.61 |
| Q1 2024 | -8,187 | Reduce 37.68% | 13,541 | $29.22 |
| Q4 2023 | -589 | Reduce 2.64% | 21,728 | $33.74 |
| Q3 2023 | +3,203 | Add 16.76% | 22,317 | $30.68 |
| Q2 2023 | -11,335 | Reduce 37.23% | 19,114 | $40.07 |
| Q1 2023 | +30,449 | New Buy | 30,449 | $40.81 |
| Q4 2022 | -5,079 | Sold Out | 0 | $0.00 |
| Q3 2022 | +1,097 | Add 27.55% | 5,079 | $53.16 |
| Q2 2022 | -2,526 | Reduce 38.81% | 3,982 | $58.26 |
| Q1 2022 | -18,066 | Reduce 73.52% | 6,508 | $76.37 |
| Q4 2021 | +4,198 | Add 20.60% | 24,574 | $60.19 |
| Q3 2021 | +12,794 | Add 168.74% | 20,376 | $56.00 |
| Q2 2021 | +301 | Add 4.13% | 7,582 | $60.67 |
| Q1 2021 | -4,726 | Reduce 39.36% | 7,281 | $70.05 |
| Q4 2020 | +137 | Add 1.15% | 12,007 | $59.80 |
| Q3 2020 | -1,732 | Reduce 12.73% | 11,870 | $60.15 |
| Q2 2020 | -46,637 | Reduce 77.42% | 13,602 | $52.49 |
| Q1 2020 | +31,593 | Add 110.29% | 60,239 | $33.53 |
| Q4 2019 | -22,270 | Reduce 43.74% | 28,646 | $45.31 |
| Q3 2019 | +7,571 | Add 17.47% | 50,916 | $38.06 |
| Q2 2019 | +35,137 | Add 428.08% | 43,345 | $43.49 |
| Q1 2019 | +8,208 | New Buy | 8,208 | $38.01 |
| Q2 2015 | -9,319 | Sold Out | 0 | $0.00 |
| Q1 2015 | +9,319 | New Buy | 9,319 | $88.85 |
| Q4 2014 | -6,946 | Sold Out | 0 | $0.00 |
| Q3 2014 | -2,540 | Reduce 26.78% | 6,946 | $96.89 |
| Q2 2014 | +9,486 | New Buy | 9,486 | $91.82 |
Joel Greenblatt's Pacira BioSciences Investment FAQs
Joel Greenblatt first purchased Pacira BioSciences, Inc. (PCRX) in Q2 2014, acquiring 9,486 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Pacira BioSciences, Inc. (PCRX) for 34 quarters since Q2 2014.
Joel Greenblatt's largest addition to Pacira BioSciences, Inc. (PCRX) was in Q3 2024, adding 90,913 shares worth $1.37 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 44,939 shares of Pacira BioSciences, Inc. (PCRX), valued at approximately $1.02 M.
As of the Q1 2026 filing, Pacira BioSciences, Inc. (PCRX) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Pacira BioSciences, Inc. (PCRX) was 90,913 shares, as reported at the end of Q3 2024.